Activin receptor signaling pathway (None standardized for the pathway; for receptors, common abbreviations include ACVR1, ACVR1B, ACVR1C (type I), and ACVR2A, ACVR2B (type II))

The activin receptor ligand pathway refers collectively to the signal transduction cascade initiated by ligands of the transforming growth factor beta (TGF-beta) superfamily—such as activins, myostatin, bone morphogenetic proteins (BMPs), nodal—binding their cognate cell surface activin receptors. These are heteromeric complexes composed of type II and type I serine/threonine kinase transmembrane proteins. Upon ligand binding to a type II subunit (e.g., ACVR2A or ACVR2B), this recruits and phosphorylates a type I subunit (e.g., ALK4/ACVR1B), which then activates intracellular SMAD proteins that regulate gene expression in the nucleus. This system regulates diverse biological processes including cell proliferation/differentiation, apoptosis, tissue homeostasis, reproduction/developmental patterning, muscle mass regulation—and is implicated in diseases such as cancer cachexia/muscle wasting syndromes and neurodegenerative disorders. Therapeutically relevant interventions include antagonists that block ligand-receptor interactions ("ligand traps") or small molecules that inhibit downstream effectors. Drugs like stamulumab have been developed as myostatin inhibitors acting via these pathways. Because “activin receptor ligand pathway” describes an entire network rather than one discrete molecular entity—and because there are multiple distinct but related activin receptors—the term is not precise enough for structured drug target annotation without further specification.

Other names

Activin signaling pathwayTGF-beta/activin signalingActivin type I and type II receptors

Ligand trap/antagonist blocks ligand binding to activin receptors, inhibiting downstream SMAD-mediated transcriptional activity and associated biological effects such as muscle wasting or tumor progression.